Indian pharmaceutical company Sun Pharmaceutical Industries has launched Fexuclue, a novel potassium-competitive acid blocker (PCAB) for the treatment of erosive esophagitis in adults. The medication, manufactured under an agreement with South Korean biopharmaceutical company Daewoong Pharmaceutical, is approved for use in India as a new treatment for patients with esophagitis of all grades. Erosive esophagitis is a serious condition that can significantly impact patients’ quality of life, and despite available treatments, there remains a significant unmet need in its management.
Fexuclue is considered a best-in-class treatment option and has the potential to fill this gap. Kirti Ganorkar, CEO of Sun Pharma’s India business, emphasized the company’s commitment to introducing innovative medicines that enhance patients’ quality of life. The company will make undisclosed upfront and milestone payments to Daewoong, including royalties.
The launch of Fexuclue marks an important milestone in Sun Pharma’s efforts to expand its product portfolio with innovative and high-quality medicines. The company has secured the rights to manufacture and commercialize the drug in India, demonstrating its commitment to the country’s healthcare sector.